DXCM vs KMTS
DXCM: Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data. KMTS: Kestra makes the ASSURE wearable cardioverter-defibrillator (WCD), a wireless cardiac monitoring and treatment device for patients at high risk of sudden cardiac death, as part of its Cardiac Recovery System platform.
Side-by-side fundamentals
| Metric | DXCM | KMTS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $73.37 | $22.82 | |
| Market cap as of 2026-07-31 | $28.5B | $1.3B | |
| P/E as of 2026-07-31 | 30.66 | n/a | |
| PEG as of 2026-07-31 | 1.26 | n/a | |
| Net margin as of 2026-07-31 | +19.3% | -138.4% | DXCM higher |
| Gross margin as of 2026-07-31 | +63.4% | +51.4% | DXCM higher |
| Operating margin as of 2026-07-31 | +21.4% | -141.7% | DXCM higher |
| ROE as of 2026-07-31 | +33.8% | -58.8% | DXCM higher |
| ROA as of 2026-07-31 | +13.4% | -42.1% | DXCM higher |
| Debt / equity as of 2026-07-31 | 0.44 | 0.16 | KMTS lower |
| Revenue growth (YoY) as of 2026-07-31 | +16.1% | +59.0% | KMTS higher |
| Revenue CAGR (3y) SEC XBRL | +17.0% | n/a | |
| Beta as of 2026-07-31 | 1.41 | 1.62 | |
| 1-year return as of 2026-07-27 close | -17.6% | +37.9% | KMTS higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.